Trial Profile
A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302) [EXTENSION OF 700025455]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Retigabine (Primary)
- Indications Epilepsy; Partial epilepsies
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 22 Dec 2021 This trial has been completed in Hungary and Belgium, according to European Clinical Trials Database.
- 17 Jul 2018 Status changed from active, no longer recruiting to discontinued.
- 11 Jun 2018 Planned End Date changed from 31 May 2018 to 22 Jun 2018.